Abvc Biopharma (ABVC) Return on Capital Employed (2011 - 2026)
Abvc Biopharma's (ABVC) quarterly Return on Capital Employed came in at 53.52% in Q1 2026, up 23931.0% YoY from N/an in Q1 2025, and down 12.07% on a QoQ basis from 47.76% in Q4 2025.
Abvc Biopharma (ABVC) Return on Capital Employed (2011 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 11 years of Return on Capital Employed data on file, last reported at 53.52% in Q1 2026.
- Quarterly Return on Capital Employed rose 23931.0% year-over-year to 53.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53.52% (up 23931.0% YoY) and the FY2025 annual result came in at 87.88%, up 74263.0% from the prior year.
- Return on Capital Employed slipped to 53.52% in Q1 2026, from 47.76% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 47.76% in Q4 2025 to a low of 661.21% in Q1 2024.
- A 5-year average of 245.54% and a median of 223.72% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed slumped 44867 bps — and 2025, when it surged 37947 bps.
- Tracing ABVC's Return on Capital Employed over 5 years: stood at 336.89% in 2022, then jumped by 64 bps to 121.97% in 2023, then slumped by 250 bps to 427.23% in 2024, then surged by 89 bps to 47.76% in 2025, then decreased by 12 bps to 53.52% in 2026.
- The last three Return on Capital Employed figures came in at 53.52% (Q1 2026), 47.76% (Q4 2025), and 71.61% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Abvc Biopharma | 23.34 Mn | 23.34 Mn | - | -46.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -46.97% |
| Mar 31, 2026 | -53.52% |
| Dec 31, 2025 | -47.76% |
| Sep 30, 2025 | -71.61% |
| Jun 30, 2025 | -351.20% |
| Mar 31, 2025 | -292.83% |
| Dec 31, 2024 | -427.23% |
| Sep 30, 2024 | -271.16% |
| Jun 30, 2024 | -360.97% |
| Mar 31, 2024 | -661.21% |
| Dec 31, 2023 | -121.97% |
| Sep 30, 2023 | -123.64% |
| Jun 30, 2023 | -257.33% |
| Mar 31, 2023 | -212.54% |
| Dec 31, 2022 | -336.89% |
| Sep 30, 2022 | -223.72% |
| Jun 30, 2022 | -179.80% |
| Mar 31, 2022 | -180.85% |
| Dec 31, 2021 | -125.41% |
| Sep 30, 2021 | -140.19% |